MHRA to Lead Industry Consortium to Advance Apps, Social Media for Reporting Adverse Drug Reactions

From DCAT Value Chain Insights (VCI)

By Regulatory News posted 09-09-2014 06:07

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) is leading a consortium of organizations, including European medicines regulators, academics, and the pharmaceutical industry in a three-year project to develop new ways of gathering information on suspected adverse drug reactions (ADRs). The project, known as WEB-RADR, is in response to the rapid adoption of smartphones, apps, and social media for discussing issues with medicines and health.  

It will work to develop a mobile app for healthcare professionals and the public to report suspected ADRs to national EU regulators. It will also investigate the potential for publicly available social media data for identifying potential drug-safety issues. All social media data used within the project will be appropriately anonymized to protect data privacy.

In addition to reporting suspected ADRs the app could also serve as a platform to send accurate, timely, and up-to-date medicines information to patients, clinicians, and caregivers.

WEB-RADR will also examine the value of these new tools for monitoring drug safety. It will help to develop recommendations for medicines regulators and the pharmaceutical industry internationally on how these should be used alongside existing systems.

This project is funded though the Innovative Medicines Initiative, a public/private partnership between the European Commission and European Federation of Pharmaceutical Industries and Associations.

Source: MHRA


Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT). 

Learn more and sign up to receive a complimentary subscription